2-(benzylamino)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4(3H)-one | 1341213-06-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 2-(benzylamino)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4(3H)-one
• 英文别名: 2-(benzylamino)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one
• CAS: 1341213-06-6
• 化学式: C₁₈H₁₅N₅O
• 分子量: 317.35
• InChiKey: LBQYEFVUBRVLEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  82.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(6-methoxy-2-(methylsulfonyl)pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridine 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2-(benzylamino)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4(3H)-one
  参考文献：
  名称：

  Aminopyrimidinone Cdc7 Kinase Inhibitors

  摘要：

  We have investigated the SAR of a series of pyrimidinone-containing Cdc7 kinase inhibitors. A wide range of amine substitutions give potent compounds with activities (K-i) less than 1 nM. Kinase selectivity is reasonable and cytotoxicity corresponds to inhibition of MCM2 phosphorylation. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.041

文献信息

• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Penning Thomas D.

  公开号：US20110257152A1

  公开（公告）日：2011-10-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及式（I）的化合物或药物可接受的盐，其中R1a，R1b，R1c，X和Y在说明中有定义。本发明还涉及含有所述化合物的组合物，其对于抑制Cdc7等激酶以及治疗癌症等疾病的方法是有用的。
• US8822446B2
  申请人：——

  公开号：US8822446B2

  公开（公告）日：2014-09-02
• US9181246B2
  申请人：——

  公开号：US9181246B2

  公开（公告）日：2015-11-10
• [EN] PYRROLOPYRIDINE INHIBITORS OF KINASES<br/>[FR] INHIBITEURS PYRROLOPYRIDINE DE KINASES
  申请人：ABBOTT LAB

  公开号：WO2011133388A1

  公开（公告）日：2011-10-27

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, Formula (I) wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
• Aminopyrimidinone Cdc7 Kinase Inhibitors
  作者：Keith W. Woods、Chunqiu Lai、Julie M. Miyashiro、Yunsong Tong、Alan S. Florjancic、Edward K. Han、Niru Soni、Yan Shi、Loren Lasko、Joel D. Leverson、Eric F. Johnson、Alexander R. Shoemaker、Thomas D. Penning

  DOI：10.1016/j.bmcl.2012.01.041

  日期：2012.3

  We have investigated the SAR of a series of pyrimidinone-containing Cdc7 kinase inhibitors. A wide range of amine substitutions give potent compounds with activities (K-i) less than 1 nM. Kinase selectivity is reasonable and cytotoxicity corresponds to inhibition of MCM2 phosphorylation. (c) 2012 Elsevier Ltd. All rights reserved.